A multi-omic systems map of glial lineages, niches and signalling.
Multi-omic systems map of glial lineages, niches and signalling.
GLIO-SYS is one of 11 subsystems that compose AURORA-GLIO. It is independently usable but shares the same patient representation, provenance log and governance layer as every other AURORA module.
Glioma is not a single cell type behaving badly — it is an ecosystem. GLIO-SYS is the substrate's view of that ecosystem: a multi-omic systems map of glial lineages, niches and signalling, anchored in published single-cell atlases and aligned to spatial transcriptomics where it is available.
The atlas is not a deliverable. It is a coordinate system. Every other GLIO subsystem refers back to it: the foundation model uses it for representation, the infiltration solver uses it for cell-type priors, the diagnosis layer uses it to resolve ambiguous calls. Without a shared coordinate system, the modules collapse back into the four worlds they were meant to bridge.
GLIO-SYS can be installed standalone, or pulled in as part of the full AURORA-GLIO stack. Both ship the same code and weights, signed end-to-end. Pilot partners have access today; public alpha opens Q4 2026.
pip install aurora-glio[sys] aurora glio.sys atlas show # → glial lineages · neoplastic compartments · TME states # → spatial overlays available for ~38% of TCGA cohort
GLIO-SYS moves faster when the right people are in the room. Whether you carry a service line, a registry, or a few quiet weekends — there is a way in.
Sponsor GLIO-SYS for your unit. Co-design the surface, the audit log and the override semantics with the team that built it. Pilot sponsors keep a council seat for the duration.
Run a research question on GLIO-SYS. Federation means you can train across populations you cannot see alone. Whitepapers carry co-authorship, not acknowledgements.
GLIO-SYS ships starter tasks tagged 'good-first-issue' on the pilot repo. SDKs in Python, TypeScript and Rust at public alpha. MIT, no CLA.
AURORA is in private pilot today and opens to the world at public alpha in Q4 2026 under MIT. If you carry the weight of these diseases — as a clinician, scientist, builder, patient or advocate — there is a seat at the table.